Jiangsu Hengrui Medicine Co., Ltd.

This study tests an experimental drug called SHR-A1904 in about 83 people with advanced solid tumors (stomach or pancreatic cancer) that have not responded to standard treatments. The main goals are to check the drug's safety, find the best dose, and see if it can shrink tumors. …

This study tests a new drug called HRS-4508 combined with other cancer treatments for people with advanced non-small cell lung cancer that has stopped responding to standard therapy. About 100 adults aged 18 to 75 will participate. The goal is to find the best dose and see if the…

This study tests a new drug called HRS-6209 combined with other treatments for breast cancer. About 80 women aged 18-75 whose cancer has worsened after prior therapy will participate. The goal is to find safe doses and see if the combination shrinks tumors.

This study tests a new drug called SHR-A1811 in 60 women with advanced cervical cancer that has come back or spread and no longer responds to standard treatments. The drug targets a protein called HER2 on cancer cells. The main goal is to see how many patients' tumors shrink. Par…

This study tests a new drug, HRS-1167, combined with two standard treatments (abiraterone and prednisone) in men with metastatic prostate cancer that has spread. The goal is to find the best dose and see if the combination is safe and helps control the disease. About 66 men aged …

This study tests a new drug called FH-006, given alongside other cancer treatments, for people with advanced non-small cell lung cancer. The goal is to find the best dose and see if the combination is safe and helps shrink tumors. About 200 adults aged 18 to 75 who cannot have su…

This phase 3 trial tests whether a new drug called SHR-A1811 works better than standard chemotherapy for people with ovarian, fallopian tube, or primary peritoneal cancer that has stopped responding to platinum-based treatments. About 300 participants will be randomly assigned to…

This early-stage study tests a new injection called SHR-1049 in 200 adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety, find the best dose, and see if the drug can shrink tumors. Participants will be closely monito…

This Phase 3 trial tests whether a new combination of drugs (irinotecan liposome, oxaliplatin, 5-FU, and calcium folinate) works better than the current standard (nab-paclitaxel and gemcitabine) for people with metastatic pancreatic cancer that hasn't been treated yet. About 662 …

This early-stage study tests a new drug called HRS-2329 in people with advanced solid tumors that have RAS mutations or amplifications. The main goals are to check safety, find the best dose, and see how the drug moves through the body. About 120 adults aged 18-75 who have tried …

This study tests a new drug, HRS-4642, combined with other cancer treatments in people with advanced solid tumors that have a specific KRAS G12D mutation. The goal is to find the safest dose and see if the combination shrinks tumors. About 118 adults aged 18-75 with good performa…

This study tests a new drug called HRS-9190 to see how well it relaxes muscles during surgery compared to a standard drug. About 60 adults having planned surgery will get either HRS-9190 or the standard drug. The main goal is to measure how quickly muscle function returns after s…

This early-stage study tests a new injection called SHR-3167 in 55 adults with type 2 diabetes. The goal is to see how the drug moves through the body and how well it controls blood sugar. Participants will be monitored for side effects and low blood sugar events.

This study tests a new drug called SHR0302, given as a pill alone or with a gel, for people with non-segmental vitiligo (white patches on skin). The goal is to see if it can reduce the size of the patches, especially on the face. About 176 adults aged 18 to 75 will take part, and…

This study tests a new drug called HRS-9190 against a standard muscle relaxant (rocuronium) in 90 adults having planned surgery under general anesthesia. The goal is to see how quickly muscle function returns after the last dose. Researchers will also check safety and how well th…

This phase 3 trial tests a radioactive drug (lutetium-177) combined with standard-dose octreotide against high-dose octreotide alone in 220 adults with advanced gastrointestinal or pancreatic neuroendocrine tumors that cannot be removed by surgery. The goal is to see if the combi…

This phase 3 trial tests whether a new drug called rezvilutamide, combined with hormone therapy, works better than the current standard enzalutamide plus hormone therapy for men with low-volume metastatic hormone-sensitive prostate cancer. About 206 participants will receive one …

This study looks at whether a special long-acting numbing medicine (bupivacaine liposome) can safely control pain in children after orthopedic surgery. About 232 kids aged 6 to 17 will receive the injection at the surgical site. Researchers will track side effects and how much ex…

This study tests a sedative called remimazolam in 240 children and teens having surgery. The goal is to see if it works well and is safe for keeping them calm and stable during the procedure. Participants must be having elective surgery and meet weight requirements, but those nee…

This study tests a new, long-lasting form of the painkiller bupivacaine for people recovering from chest surgery. The goal is to see if it can reduce pain during movement and coughing for up to 72 hours. About 96 adults having a specific type of lung surgery will receive the drug…

This early-stage study is testing a new injectable drug called HRS-2183 in 42 healthy Chinese adults aged 18 to 45. The main goal is to check if the drug is safe and how the body processes it after one or more doses. Participants will be closely monitored for side effects. This s…